Assessment of Prognostic Ability of Galectin-1, -3, and -9 in Lung Cancer Patients
Hayden Shuster(University of South Carolina), Anna V. Blenda(University of South Carolina), William J. Edenfield(Prisma Health), Avery Funkhouser(National Institutes of Health), Julie Martin(Prisma Health), Lorie Allen(Prisma Health)
Cited by 1
Related Papers
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
|Journal for ImmunoTherapy of Cancer|2020|117
Increased Circulating Levels of Galectin Proteins in Patients with Breast, Colon, and Lung Cancer
|Cancers|2021|36
Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis
|Current Issues in Molecular Biology|2021|33